TI
DNTH icon

Trexquant Investment’s Dianthus Therapeutics DNTH Stock Holding History

Trexquant Investment’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.96M Buy
59,077
+53,861
+1,033% +$3.12M 0.04% 651
2025
Q4 		$215K Buy
+5,216
New +$202K ﹤0.01% 1510
2020
Q3 		– Sell
-1,448
Closed -$174K – 1261
2020
Q2 		$174K Buy
+1,448
New +$204K 0.01% 1069

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Trexquant Investment's DNTH Position: Q1 2026 in Review

Trexquant Investment increased its Dianthus Therapeutics (DNTH) stake by 1,033% in Q1 2026, buying an estimated $3.12M and bringing the position to 59,077 shares worth $4.96M. The position accounts for 0.04% of the portfolio, ranked #651.

Trexquant Investment first reported a position in DNTH in Q2 2020 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Trexquant Investment held 59,077 shares of Dianthus Therapeutics worth $4.96M as of Q1 2026.
  • Trexquant Investment bought 53,861 Dianthus Therapeutics shares in Q1 2026, an estimated $3.12M.
  • Dianthus Therapeutics made up 0.04% of Trexquant Investment's portfolio in Q1 2026, its #651 holding.
  • Trexquant Investment first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.